Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PDC 1421

Drug Profile

PDC 1421

Alternative Names: BLI-1005; PDC-1421

Latest Information Update: 08 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medical and Pharmaceutical Industry Technology and Development Center
  • Developer BioLite Inc
  • Class Antidepressants; Traditional Chinese medicine
  • Mechanism of Action Norepinephrine plasma membrane transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 12 Feb 2019 BioLite plans a phase I/II trial for Major depressive disorder in USA (PO) (NCT03833206)
  • 24 Jun 2018 Biomarkers information updated
  • 08 Sep 2017 Phase-II development is ongoing in USA and Taiwan (PO) (NCT02395978)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top